Browsing Modes for Business Users

CD55 antibody | 67

Product Code Applications Pack Size List Price Your Price Qty
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
F 100 Tests loader
List Price Your Price

Mouse anti Human CD55 antibody, clone 67 recognizes the human CD55 cell surface antigen, a GPI linked molecule also known as decay accelerating factor (DAF). CD55 is expressed by a wide range of cell types.

CD55 is the complement regulatory protein, decay accelerating factor (DAF) (Lublin and Atkinson 1989). Human CD55 is a ~70 kDa glycoprotein (in erythrocytes) anchored in the membrane by glycosylphosphatidylinositol tail. In other cells the apparent molecular weight is somewhat larger. It has a substantial content of O-glycans, and also on N-glycan. DAF binds to activated C4b or C3b complement fragments on the cell surface, preventing the assembly and accelerating the decay of both classical and alternative pathways. DAF carries the Cromer related blood group antigens.

DAF has a wide distribution on cells in non-haematopoietic tissues, particularly epithelium and is found at the fetal-maternal interface in placenta (Holmes et al. 1990 and Yang et al. 2009). Soluble forms of DAF are found, for example, in plasma, saliva and urine (Medof et al. 1987). The antigen on erythrocytes is pronase and chymotrypsin sensitive, but resistant to trypsin.

Target Species
Product Form
Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
Reconstitute with 1 ml distilled water
Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09% sodium azide (NaN3)
1% bovine serum albumin
5% sucrose
K562 cells
Max Ex/Em
Fluorophore Excitation Max (nm) Emission Max (nm)
RPE 488nm laser 496 578
For research purposes only
12 months from date of despatch

Prior to reconstitution store at +4°C. Following reconstitution store at +4°C.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat 1/2
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10μl of the suggested working dilution to label 106 cells in 100&mul

How to Use the Spectraviewer

Watch the Tool Tutorial Video ▸
  • Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
  • Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
  • Select the lasers and filters you wish to include
  • Select combined or multi-laser view to visualize the spectra

Description Product Code Applications Pack Size List Price Your Price Quantity
Mouse IgG1 Negative Control:RPE MCA928PE F 100 Tests
List Price Your Price
Description Mouse IgG1 Negative Control:RPE

Description Product Code Applications Pack Size List Price Your Price Quantity
Human Seroblock BUF070A F 50 Test
List Price Your Price
Description Human Seroblock
Human Seroblock BUF070B F 200 Test
List Price Your Price
Description Human Seroblock

References for CD55 antibody

  1. Hadam, M.R. (1989) In Leucocyte Typing IV: White Cell Differentiation Antigens.
    Edited by Knapp, W. et al. Oxford University Press pp 694-697.
  2. Holmes, C.H. et al. (1990) Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy.
    J Immunol. 144 (8): 3099-105.
  3. O'Brien, D.P. et al. (2009) Regulation of the Helicobacter pylori cellular receptor decay-accelerating factor.
    J Biol Chem. 283: 23922-30.
  4. Kraan, M.C. et al. (2004) T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis.
    Ann Rheum Dis. 63: 483-8.
  5. van Holten, J. et al. (2005) A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
    Ann Rheum Dis. 64 (1): 64-9.
  6. Yang, P. et al. (2009) Expression and modulation of RPE cell membrane complement regulatory proteins.
    Invest Ophthalmol Vis Sci. 50: 3473-81.
  7. van de Sande, M.G. et al. (2011) Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase.
    Ann Rheum Dis. 70: 772-7.
  8. Araten, D.J. et al. (2005) A quantitative measurement of the human somatic mutation rate.
    Cancer Res. 65: 8111-7.
  9. View The Latest Product References
  10. Mo, B. et al. (2006) ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium.
    Biol Reprod. 75: 387-94.
  11. Vos, K. et al. (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
    Arthritis Rheum. 56 (3): 772-8.
  12. de Launay, D. et al. (2010) Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis.
    Am J Pathol. 177: 3010-24.
  13. Gheorghe, K.R. et al. (2011) Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression.
    PLoS One. ;6: e16378.
  14. Abreu, J.R. et al. (2009) The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue.
    Arthritis Res Ther.11(4):R121.
  15. Thurlings, R.M. et al. (2008) Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.
    Ann Rheum Dis. 67 (7): 917-25.
  16. Edginton S et al. (2016) Effects of Rituximab and Infliximab Treatment on Carboxypeptidase B and Its Substrates in RA Synovium.
    J Rheumatol. 43 (5): 846-54.

Further Reading

  1. Lublin, D.M. & Atkinson, J.P. (1989) Decay-accelerating factor: biochemistry, molecular biology, and function.
    Annu Rev Immunol. 7: 35-58.
  2. Daniels, G. (1989) Cromer-related antigens--blood group determinants on decay-accelerating factor.
    Vox Sang. 56 (4): 205-11.

Immunohistology - Frozen

Immunohistology - Paraffin

Entrez Gene
GO Terms
GO:0005576 extracellular region
GO:0005887 integral to plasma membrane
GO:0005625 soluble fraction
GO:0006958 complement activation, classical pathway
GO:0007204 elevation of cytosolic calcium ion concentration
GO:0031225 anchored to membrane
GO:0045087 innate immune response
GO:0045121 membrane raft
GO:0045730 respiratory burst


1114 1608

If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.

View more products with CD55 specificity

Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"

View all Anti-Human Products
Please note